Cascadian Therapeutics (CASC)

[cash2go]

Trying to determine expected control arm median survival


Stimuvax phase II trial

171 patients IIIB LR or stage IIIB with malignant pleural effusion, and stage IV
results were not statistically significant

subgroup stable or responding disease after any first-line
Stimuvax arm compared with BSC alone (49% (n=17) vs. 27% (n=8))
median survival 30.6 months vs. 13.3 months, respectively

http://www.advfn.com/news_Stimuvax-Phase-II-data-highlight-three-year-survival-results-for-patients-with-n_22137963.html